anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Physiotherapists trained to deliver biopsychosocial interventions for complex musculoskeletal pain problems often report difficulties in confidence and competency at the end of training. Cognitive Functional Therapy (CFT) is an individualized biopsychosocial intervention and understanding the facilitators and barriers to training in CFT will help inform future training programs. This study aimed to explore physiotherapists' and trainers' perceptions of the process of developing competency in CFT.
METHODS: A cross-sectional qualitative design using interviews of 18 physiotherapists and two trainers investigated training in CFT for persistent LBP via reflexive thematic analysis.
RESULTS: Physiotherapists reported undergoing a complex behavior change process during training. Four themes emerged: 1) Pre-training factors; 2) Behavior change process; 3) Physiotherapy culture and context; and 4) Confident competence and beyond. Key components included graduated practice exposure linked to experiential learning with feedback and clear competency guidelines. Pre-training and contextual factors were facilitators or barriers depending on the individual. Physiotherapists supported ongoing learning, even after competency was achieved.
CONCLUSIONS: This study provides insight into the processes of change during progress toward competency in CFT. It highlights facilitators and barriers to competency including physiotherapy culture and the clinical environment. The study also describes important educational components, including experiential learning and clinical integration, which may be used to inform future post-graduate training.
For Part 2b, up to 30 subjects with advanced solid malignant tumors, with a preference for those with advanced ovarian cancer, will be enrolled and treated at the MTD or MAD. This number of subjects should allow demonstrating U3-1565 has anti-tumor impact by showing treatment-induced changes in pharmacodynamic biomarkers and clinical activity. Ovarian cancer may be more likely to be impacted by U3 1565 than other tumors, considering that in this cancer, high levels of HB-EGF have been associated with an unfavorable clinical outcome. Six subjects will be initially treated; at which point, a safety analysis will be conducted after these initial subjects have completed the first cycle of treatment, to allow the reevaluation of the appropriateness of the dosing level.
The SYNTAX III REVOLUTION Trial is a multicenter, all-comers trial (either isolated unprotected left-main or 3-vessel disease with or without left-main disease and candidate for either CABG or PCI treatment). In SYNTAXIII REVOLUTION a diagnostic coronary angiography and a diagnostic coronary Multislice CT are performed to allow the Heart Team to assess the optimal revascularization strategy. In a normal hospital setting the angiography is considered standard of care. The multislice CT can already also be part of the diagnosis and is at the discretion of the physician. After the images of both modalities are available, the patient will no longer participate in the trial. Next step is randomization of Heart Team A and Heart B to the sequence of availability of images, i.e. randomizing whether Heart Team A will review the angiography first or the multislice CT and, automatically, Heart B the other modality. The Heart Teams need to make a decision between surgical or percutaneous treatment according to either the conventional angiography or the multislice CT angiography assessment. In addition, the incremental value of FFRCT in the decision making of the Heart Team arm allocated primarily to the assessment of the MSCT (CT first algorithm) will be a secondary endpoint. No intervention to the patient's treatment takes place

i
Background National guidelines no longer recommend adults 60 years of age and older to begin treatment with low-dose daily aspirin for primary prevention of atherosclerotic cardiovascular disease (CVD) due to a lack of proven net benefit and a higher risk of bleeding. Objective The objective of this cross-sectional retrospective analysis was to evaluate the appropriateness of low-dose aspirin prescribing and subsequent gastrointestinal bleeding in older persons receiving primary care in a large academic health system. Setting Large, academic health system within Colorado. Patients Patients with an active order for daily low-dose aspirin as of July 1, 2021, were assessed for appropriateness based on indication (primary vs secondary prevention) and use of a concomitant proton-pump inhibitor (PPI). Incident gastrointestinal bleeds (GIBs) in the subsequent 12 months and GIB risk factors were also evaluated. Results A total of 19,525 patients were included in the analysis. Eighty-nine percent of patients identified as White and 54% identified as male. Of the total cohort, 44% had CVD and 19% were co-prescribed a PPI. GIB occurred in 247 patients (1.27%) within the subsequent year. Risk factors significantly associated with a GIB within 1 year included: history of GIB, history of peptic ulcer disease, other esophageal issue (esophagitis, Barrett's esophagus, Mallory Weiss tears, etc.), 75 years of age or older, and history of gastroesophageal reflux disease. Conclusion This evaluation found that many older persons at this institution may be inappropriately prescribed aspirin, providing opportunities for pharmacists to improve medication safety by deprescribing aspirin among primary prevention patients or potentially co-prescribing a PPI in secondary prevention patients.
The Oculosense system, is an advanced tool in dentistry for analyzing occlusion, especially in denture equilibration. It includes an ultra-thin sensor and software that records and displays the force and timing of occlusal contacts in real-time. This system provides detailed data on force distribution, contact timing, and the center of force, offering 2D and 3D visualizations. It allows for precise, dynamic adjustments of dentures by identifying high-pressure areas and premature contacts. Despite its benefits, including high precision and quantifiable data, it is costlier and requires specialized training.
The utility model relates to a tooth paste, including a soft plastic film and a base (1). A jelly with medicament is overlaid on one side of the soft plastic film. The side of the soft plastic film is laminated onto the base (1). A crack (6) is cut on the soft plastic film, dividing the soft film into two parts: main pasting film (4) and the anti-overflow part outside the main pasting film (3). The soft plastic film is divided into two parts: the main pasting film and the anti-overflow part outside the main pasting film. The main pasting film is the effective part. The overflow part of the jelly would not do any affect onto the main pasting film and the effective content would not be lost. What's more, the jelly overflowing from the cutting crack would make up for the soft plastic film from two sides of the crack. The medicament dosage on the edge of the main pasting film can be effectively ensured.
Patients with petrous bone cholesteatoma most commonly present with hearing loss and facial paralysis. Other clinical presentations can include otorrhea, tinnitus, aural fullness, otalgia, and dizziness. Here, we report a patient with petrous bone cholesteatoma who presented with cerebrospinal fluid rhinorrhea. This patient was initially misdiagnosed with rhinogenic cerebrospinal fluid leakage, and was finally diagnosed with the supralabyrinthine type of petrous bone cholesteatoma. During the surgical repair through the transmastoid trans-superior semicircular canal approach, the fistula was found in the superior wall of the internal auditory canal. He had satisfactory outcomes after the surgery, with no recurrent cerebrospinal fluid rhinorrhea.
The benzothiazole derivative of general formula and its enantiomer is prepared as follows: (1) A compound of general formula(VI) is replaced by a halogen and is reacted with alkyl or acylhalide under alkali condition to obtain a compound of general formula(VII). (2) After halogen-lithium replacement reaction of a compound(VII), a compound of general formula(VIII) is obtained by reacting with dimethyl oxalate. (3) And then an intermediate of general formula(i) is produced by reacting a compound of general formula(VIII) with methoxyl amine under basic condition or wittig reaction with phosphorous ylide. A benzothiazole is used for eliminating botanical germs or animal fungus. In the above formula, R1, R2 and R3 is independent hydrogen, halogen atom and like respectively. X is nitrogen or hydrocarbon.
FIELD: veterinary medicine. SUBSTANCE: invention relates to specifically diagnosing infection diseases in animals. Tuberculosis micobacteria are grown on nutrient medium for 2 months and destroyed by  60 Co gamma-radiation in dose nutrient medium (1.0-2.0) x 10 6  R, concentration of tuberculoprotein in nutrient medium being 1,2±0,3 mg/ml. Culture liquid is separated and centrifuged. Supernatant is removed and remaining solids are bagged and autoclaved. In such a way, yield of desired product is 3.9-5.3 times increased. EFFECT: increased yield and eliminated release of tuberculosis toxicoallergens , trichloroacetic acid, and ammonia. 3 ex
Approximately 5.4 million individuals in the United States are diagnosed with non-melanoma skin cancers (NMSC) annually, with the incidence increasing over time. Twenty-five percent are cutaneous squamous cell carcinomas (cSCC), which affect up to 1,350,000 individuals and result in up to 12,000 deaths annually in the US alone. Immunosuppressed patients are particularly vulnerable to the development of highly aggressive or catastrophic cSCC. Patients receiving immunosuppressive therapy, such as solid organ transplant recipients (SOTRs), and HIV/AIDS patients have an estimated 60 to 250-fold increased risk of cSCC development. In renal SOTRs, cSCC represents over 70% of all malignancies that develop, with an incidence up to 200 times that of the general population. Post-transplant cSCC occurs at a younger age and is more aggressive than in non-transplant cohorts, with 30% of cSCC recurring within 1 year and up to 8% of disease associated with metastasis. The median survival from diagnosis of metastasis is 3 years.5 Cemiplimab, an anti-PD1 antibody, recently became the first agent to achieve regulatory approval for the treatment of advanced cSCC; however, due to the risk of graft rejection, the role of immunological checkpoint blockade in the SOTR population is extremely limited. Thus, although surgical excision is effective for sporadic cSCC, there remains a large unmet medical need for novel strategies for treatment and/or prevention of multiply recurrent, locally advanced, and metastatic cSCC, particularly in immunosuppressed patients.
OBJECTIVE: Oligohydramnios (defined as amniotic fluid volume < 5 cm or deepest vertical pocket < 2 cm) is regarded as an ominous finding on prenatal ultrasound. Amniotic fluid, however, is not static, and to date, there have been no studies comparing perinatal outcomes in patients who are diagnosed with oligohydramnios that resolves and those who have persistent oligohydramnios.
STUDY DESIGN: This is a secondary analysis of a National Institutes of Health-funded retrospective cohort study of singleton gestations delivered at a tertiary care hospital between 2002 and 2013 with mild hypertensive disorders and/or fetal growth restriction (FGR). Maternal characteristics, delivery, and neonatal information were abstracted by trained research nurses. Patients with a diagnosis of oligohydramnios were identified, and those with resolved versus persistent oligohydramnios at the time of delivery were compared. The primary outcome was a composite of neonatal resuscitation at delivery: administration of oxygen, bag-mask ventilation, continuous positive airway pressure, intubation, chest compression, or cardiac medication administration. Secondary outcomes included FGR, timing, and mode of delivery.
RESULTS: Of 527 women meeting study criteria, 42 had oligohydramnios that resolved prior to delivery, whereas 485 had persistent oligohydramnios. There were no significant differences in patient demographics between groups. The gestational age at diagnosis was significantly lower for patients with resolved versus persistent oligohydramnios (median: 33.0 [interquartile range, IQR: 29.1-35.9] vs. 38.0 [IQR: 36.4-39.3], p < 0.001). There was not a substantial difference in rate of neonatal resuscitation (41 vs. 32%, p = 0.31). Patients with resolved oligohydramnios were more likely to have developed FGR than those with persistent oligohydramnios (55 vs. 36%, p < 0.02). There were no significant differences for gestational age at delivery, birth weight, or neonatal intensive care unit admission.
CONCLUSION: Patients whose oligohydramnios resolved were diagnosed earlier yet had similar rates of neonatal resuscitation but higher rates of FGR than those who had persistent oligohydramnios.
KEY POINTS: · When diagnosed earlier in pregnancy, oligohydramnios was more likely to resolve prenatally.. · Patients who were diagnosed with oligohydramnios earlier in pregnancy had higher rates of FGR.. · There were no differences in the rates of the composite outcome of need for neonatal resuscitation when comparing those with resolved versus those with persistent oligohydramnios. No differences in composite neonatal morbidity were noted between those with resolved versus persistent oligohydramnios..
The study will be a prospective interventional study with two randomized parallel groups.

Randomization will take place immediately following the identification of a potential participant. The control group will receive the standard of care for diaphyseal tibia fractures. The standard of care consists of intramedullary nailing and post-operative opioids for pain control. The interventional group will have the same surgical indication and intervention but will differ in the primary method of pain control. The study group will receive NSAIDs and a reduced dosage of opioids for pain control. Primary outcome measures will be time to union, non-union, and pain over the post-operative period measured by a VAS pain scale. Once the data collection of both groups is complete, the statistical analysis will begin to determine if there is a statistical difference between the control and study groups in the primary outcome measurements.
PURPOSE: A cosmetic composition containing 6-methoxynaringenin or derivative thereof is provided to ensure anti-aging, anti-wrinkling, and antibacterial and anti-inflammatory effect. CONSTITUTION: A cosmetic composition contains 6-methoxynaringenin or derivative thereof as an active ingredient. A cosmetic composition for anti-aging or anti-wrinkling contains 6-methoxynaringenin or derivative thereof as an active ingredient. A cosmetic composition for skin whitening contains 6-methoxynaringenin or derivative thereof as an active ingredient. The derivative is 6-methoxynaringenin-7-O-glucoside. The cosmetic composition is manufactured in the form of a solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, cleansing oil, powder foundation, emulsion foundation, wax foundation, pack, massage cream, or spray.
The invention provides a preparation method of a nanobiomaterial and is characterized in that the method comprises a step of selecting nucleic acid with required length and assembling the nucleic acid and a protein for incubation so as to obtain the nanobiomaterial. The nucleic acid can start its assembly with the protein. The assembly incubation condition makes the nucleic acid to be wrapped by the protein such that nuclease can not contact with the nucleic acid through the protein which wraps the nucleic acid. The length of the nucleic acid and granularity of the nanobiomaterial form a linear relation. The method for selecting the nucleic acid with the required length is to determine the required nucleic acid length according to the granularity of the required nanobiomaterial. The invention also provides the nanobiomaterial prepared by the above method and a nucleic acid compound. According to the method provided by the invention, the granularity of the nanobiomaterial is accurately controlled through accurate control of the nucleic acid length. The nanobiomaterial and the nucleic acid compound provided by the invention has good resistance to nuclease.
This article deals with peripheral neuroimmunological diseases and briefly outlines the currently most important aspects and treatment developments. Idiopathic inflammatory myopathies have different mechanisms of development, manifestations and prognoses. New classification systems and more specific treatment concepts have been developed. The IIMs include different subgroups. These entities can have specific autoantibodies. Diagnostically, a muscle biopsy is generally desirable for a precise diagnosis and is essential in unclear cases. Primary systemic vasculitides can be divided into different groups based on the predominant pattern of involvement, while secondary vasculitides and single organ vasculitides are also differentiated. Vasculitic myopathy cannot be equated with myositis and a reliable distinction is currently only possible by a muscle biopsy. Treatment concepts should be developed on an interdisciplinary basis. Chronic inflammatory demyelinating polyneuropathy is the most frequent immune-mediated neuropathy and is characterized by a predominant demyelination of the motor and sensory nerves. The disease course runs in phases or is progressive and leads to significant disability and reduction in quality of life, despite current standard treatment. Novel treatment approaches are currently undergoing clinical trials. Myasthenia gravis, with the leading symptom of exercise-induced muscle weakness, is caused by autoantibodies against structures of the neuromuscular endplate. Autoantibody testing is the most important pillar in the diagnosis and is now also increasingly guiding treatment decisions. Overall, peripheral neuroimmunological diseases represent a heterogeneous group. Increasing knowledge of the pathophysiology is the key to numerous developments in diagnostics and treatment, which could lead to far-reaching practical changes in the future.
Behaviours that challenge (BtC) are common in people with intellectual disability (ID) and associated with negative long-term outcomes. Reliable characterisation of BtC and behavioural function is integral to person-centred interventions. This systematic review and meta-analytic study quantitatively synthesised the evidence-base for the internal consistency, inter-rater reliability, and test-retest reliability of measures of BtC and behavioural function in people with ID (PROSPERO: CRD42021239042). Web of Science, Embase, PsycINFO and MEDLINE were searched from inception to March 2024. Retrieved records (n = 3691) were screened independently to identify studies assessing eligible measurement properties in people with ID. Data extracted from 83 studies, across 29 measures, were synthesised in a series of random-effects meta-analyses. Subgroup analyses assessed the influence of methodological quality and study-level characteristics on pooled estimates. COSMIN criteria were used to evaluate the measurement properties of each measure. Pooled estimates ranged across measures: internal consistency (0.41-0.97), inter-rater reliability (0.29-0.93) and test-retest reliability (0.52-0.98). The quantity and quality of evidence varied substantially across measures; evidence was frequently unavailable or limited to a single study. Based on current evidence, candidate measures with the most evidence for internal consistency and reliability are discussed; however, continued assessment of measurement properties in ID populations is a key priority.
PURPOSE: An expression system of a human serum albumin-TIMP-2 fusion protein and a recombinant human serum albumin-TIMP-2 protein are provided. The recombinant human serum albumin-TIMP-2 protein is useful for treatment of cancer, angiogenesis related diseases and matrix metalloprotease related diseases. CONSTITUTION: A nucleotide sequence comprises the human serum albumin gene and the TIMP-2 gene having the nucleotide sequence of SEQ ID NO: 3. A polypeptide expressed from the gene comprises the human serum albumin gene and the TIMP-2 gene having the nucleotide sequence of SEQ ID NO: 3. A vector pHSATIMP comprises (a) a promoter; (b) the human serum albumin gene and the TIMP-2 gene having the nucleotide sequence of SEQ ID NO: 3; and (c) a transcription-terminating factor. A transformant, Saccharomyces cerevisiae Y2805/pHSATIMP (KCTC 10131BP) is produced by transformation with the vector pHSATIMP.
Female subjects who previously received the active control i.e. Hepatitis A vaccine in the primary study (NCT00122681) and who received the Cervarix vaccine in the current study. The Cervarix vaccine was administered intramuscularly into the deltoid muscle of the non-dominant arm according to a 0, 1 and 6 months schedule.
The invention discloses an asymmetric chiral double-Schiff base simple synthesizing method. Asymmetric chiral double-Schiff base is produced by reacting aminomethyl compound as raw material and adequate NH3gas and aldehyde. The synthetic route is as above formula. R1, R2 are organic groups. The advantages of the invention are: di amine compound is not used as raw material and mono-amine compound is directly used for reacting with adequate NH3gas and aldehyde, finally asymmetric chiral double-Schiff base is obtained; the synthesizing method is not only applied to design and synthesize asymmetric chiral double-Schiff base with special functional group, but also to further reconstruct the asymmetric chiral double-Schiff base into required compound. The synthesizing method has features of simple device, convenient operation, short reaction time, easy generation of products, high yield, higher purity, lower cost, and being favourable for generalization and application.
The data will be obtained by applying a pre-test to the pregnant women and their spouses included in the experimental group before the application. After the pre-test data are collected, 5 sessions of haptonomy will be applied to the couples in the experimental group. Each session (Breath awareness and diaphragm breathing 5 minutes, Feminine energy attunement and heart-looking energy work 5 minutes, Physical communication with the baby in the womb with touches 10 minutes, meditation from the heart to the uterus 15 minutes, awareness of the environment, closing breath and feedback 5 minutes) It will be 40 minutes. For the effectiveness and continuity between each session, planning will be made for 3 days to 7 days. The final test will be applied 1 week after the hapatonomy application (after 5 sessions are completed).